Mirvaso FDA Approval History
FDA Approved: Yes (First approved August 23, 2013)
Brand name: Mirvaso
Generic name: brimonidine
Dosage form: Topical Gel
Company: Galderma Laboratories, L.P.
Treatment for: Rosacea
Mirvaso (brimonidine) topical gel is an alpha adrenergic agonist indicated for the topical treatment of facial erythema of rosacea.
Development timeline for Mirvaso
| Date | Article |
|---|---|
| Aug 26, 2013 | Approval Galderma Receives FDA Approval of Mirvaso for the Topical Treatment of Facial Erythema of Rosacea |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
